Baseline blood immunological profiling differentiates between Her2– breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response

Oana Tudoran^{1,2,*}Oana Virtic^{2,*}Loredana Balacescu^{1,2}Carmen Lisencu³Bogdan Fetica⁴Claudia Gherman¹Ovidiu Balacescu¹Ioana Berindan-Neagoe^{1,2,5}

¹Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof Dr Ion Chiricuță”, ²Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, ³Department of Radiotherapy I, ⁴Department of Pathology, The Oncology Institute “Prof Dr Ion Chiricuță”, ⁵Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

*These authors contributed equally to this work

Purpose: Breast cancer patients’ response to treatment is highly dependent on the primary tumor molecular features, with triple-negative breast tumors having the worst prognosis of all subtypes. According to the molecular features, tumors stimulate the microenvironment to induce distinct immune responses, baseline immune activation being associated with higher likelihood of pathologic response. In this study, we investigated the deconvolution of the immunological status of triple-negative tumors in comparison with luminal tumors and the association with patients’ clinicopathological characteristics.

Patients and methods: Gene expression of 84 inflammatory molecules and their receptors were analyzed in 40 peripheral blood samples from patients with Her2– primary breast cancer tumors. We studied the association of triple-negative phenotype with age, clinical stage, tumor size, lymph nodes, and menopausal status.

Results: We observed that more patients with estrogen (ER)/progesterone (PR)-negative tumors had grade III, while more patients with ER/PR-positive tumors had grade II tumors. Gene expression analysis revealed a panel of 14 genes to have differential expression between the two groups: several interleukins: *IL13*, *IL16*, *IL17C* and *IL17F*, *IL1A*, *IL3*; interleukin receptors: *IL10RB*, *IL5RA*; chemokines: *CXCL13* and *CCL26*; and cytokines: *CSF2*, *IFNA2*, *OSM*, *TNSF13*.

Conclusion: The expression levels of these genes have been previously shown to be associated with reduced immunological status; indeed, the triple-negative breast cancer patients presented with lower counts of lymphocytes and eosinophils than the ER/PR-positive ones. These results contribute to a better understanding of the possible role of antitumor immune responses in mediating the clinical outcome.

Keywords: triple-negative breast cancer, gene expression, molecular mechanism, immunological status, clinical outcome

Introduction

Breast cancer is the most prevalent cancer in women, in both developed and developing countries.¹ Being a heterogeneous disease, breast tumors have been classified into four main molecular subtypes: luminal A and B, Her2+, and basal-like.² The luminal subtype is characterized by a high expression of receptors for estrogen (ER) and progesterone (PR), while Her2+ tumors are negative for ER and PR, but express high levels of Her2. The basal-like class of breast tumors comprises the triple-negative breast cancers (TNBCs) and is defined by lack of ER, PR, and Her2 expression. Breast cancer treatment is designed on the basis of this classification, luminal tumors having a more

Correspondence: Oana Tudoran
Department of Functional Genomics and Experimental Pathology, The Oncology Institute “Prof Dr Ion Chiricuță”,
34-36 Republicii Street, 400015 Cluj-Napoca, Romania
Tel +40 264 590 638
Fax +40 264 590 638
Email oana.tudoran@iocn.ro

favorable prognosis, while TNBC patients are refractory to common targeted therapies, leading to the worst overall and disease-free survival of all subtypes.³

In order to achieve the most effective treatment response, it is imperative to understand the pathogenic mechanisms of breast cancer. There is a clear link between cancer and inflammation,⁴ the local microenvironment been known to aid in tumor growth and progression.⁵ Cancer microenvironment and cross talk (tumor cells, fibroblasts, endothelial cells, and infiltrating leukocytes) are tightly regulated through cytokines, key signaling molecules⁵ that can determine stimulatory or suppressive tumor responses.⁶ Due to their pleiotropic actions, cytokines are assembled in complex signaling networks that regulate tumor proliferation, progression, and host immune responses,⁷ thereby affecting prognosis and response to therapy.⁸

Studies have shown that immune activation at baseline is associated with a higher likelihood of pathological response (reviewed in Andre et al⁹); therefore, in this study, we compared the systemic cytokine expression of two molecular subtypes of breast cancer patients. The patients were grouped according to the ER/PR expression on the primary tumors, ER/PR+, Her2– patients being considered as treatment responsive, and TNBC patients as nonresponsive. With the view to better characterizing the baseline immune status, we evaluated the expression levels of a panel of 84 inflammatory molecules in the peripheral blood of our patients in correlation with histological and clinical data. These results could aid not only in the prediction of chemotherapeutic efficacy or treatment response monitoring, but also in the development of strategies to specifically modulate and reverse immune defects in breast cancer patients.

Patients and methods

Patients and blood samples

For this study, we collected 40 peripheral blood samples from patients with Her2– primary breast cancer tumors diagnosed at The Oncology Institute “I. Chiricuta”, Cluj-Napoca, Romania, between 2010 and 2012. Informed consent was obtained from all participants included in the study. This study is in accordance with the ethical standards of the institute’s research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Blood samples were collected in ethylenediaminetetraacetic acid (EDTA) anticoagulant tubes within a 4-hour interval (8 am–12 noon) before patients underwent any type of treatment: steroids, chemotherapy, or surgery. The plasma was removed and stored for protein analysis, while red blood cells were lysed

and white cells were processed for RNA isolation with TriReagent (Sigma-Aldrich, St Louis, MO, USA). RNA samples were purified with RNeasy Mini Kit (Qiagen, Valencia, CA, USA), only the RNA samples with RNA integrity number (RIN) >7 were used for further analysis. At the same time, for clinical purposes, blood was collected in EDTA tubes for full blood count with Sysmex XT-4000i (Sysmex, Kobe, Japan). AJCC criteria were used for histopathological analysis and staging of the patients. The status confirmation of ER, PR, and Her2 receptors was done by immunohistochemical analysis. Table 1 comprises the patients’ clinicopathological characteristics.

PCR array

Approximately 300 ng of the total RNA of each sample was used for cDNA synthesis using RT2 First Strand kit (SABiosciences by Qiagen, Valencia, CA, USA). The cDNA was amplified using LightCycler 480 II thermocycler (Hoffmann-La Roche, Basel, Switzerland) in 96-well Human Inflammatory Cytokines & Receptors PCR Array plates (SABiosciences by Qiagen, Valencia, CA, USA). Amplification and SYBR Green detection were performed according to the manufacturer’s recommendations. The array consists of 84 primers for chemokines, cytokines, interleukins and their receptors, five housekeeping genes for sample-to-sample normalization, and several controls for reverse transcription, genomic DNA contamination, and polymerase chain reactions (PCRs). Threshold cycle (Ct) calculations were done using the automated second derivative analysis method.

Data analysis

Correlations between clinical data were calculated using the Fisher’s exact test or the chi-square test. Cell count differences were assessed by the Mann–Whitney test. The PCR array Ct raw results were imported into the Web-based software for Cataloged and Custom Arrays (SABiosciences by Qiagen, Valencia, CA, USA) for expression analysis. Of interest to us were genes with a fold regulation cutoff ± 1.5 and a *P*-value <0.05 after the Benjamini and Hochberg correction method (**P*-value <0.05, ***P*-value <0.01, ****P*-value <0.001). The patients were grouped according to ER/PR expression on the primary tumor at diagnosis. Genes of interest and the corresponding fold regulation values were uploaded into Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Redwood City, CA, USA) for functional analysis. Using Ingenuity Knowledge Base (IKB), the genes were assigned into networks and biological functions on the basis of hierarchical organization of right-tailed Fisher’s

Table 1 Patients' clinicopathological characteristics

Number	Age (years)	Allred score			Clinical stage	TNM staging	Nottingham staging	Age at menopause (years)
		ER	PR	Her2				
1	58	0	0	0	III	T4bN3M0	II	50
2	58	0	0	0	II	T2N1M0	II	0
3	59	0	0	0	III	T3N2M0	III	N/A
4	53	0	0	0	III	T2N2M0	II	50
5	52	0	0	0	II	T2N0M0	III	48
6	45	0	0	0	III	T3N1M0	III	0
7 ^a	48	0	0	0	II (rb) + I (lb)	T2N1M0 (rb) + T1N0M0 (lb)	III	32
8	51	0	0	0	III	T4bN2M0	I	0
9	49	0	0	0	II	T2N1M0	III	0
10	50	0	0	0	III	T4bN1M0	II	0
11 ^a	55	0	0	0	III (rb) + I (lb)	T4bN2M0 (rb) + T1N0M0 (lb)	III	51
12	56	0	0	0	II	T2N1M0	III	N/A
13	59	0	0	0	III	T4cN2M0	III	52
14	60	0	0	0	II	T1N1M0	III	45
15	35	0	0	0	II	T2N1M0	III	0
16	53	0	0	0	III	T2N2M0	III	50
17	59	0	0	0	II	T2N1M0	III	46
18	42	0	0	0	N/A	T4bN2Mx	III	38
19	40	0	0	0	II	T2N1M0	III	0
20	74	0	0	0	III	T4bN2M0	III	48
21	56	0	0	0	III	T4bN1M0	III	46
22	59	0	0	0	I	T1cN0Mx	I	49
23	70	0	0	0	III	T4bNxMx	II	N/A
24	50	6	4	0	II	T2N1M0	II	50
25	45	7	7	0	II	T2N1M0	I	45
26	52	8	8	0	III	T2N2M0	III	N/A
27	54	7	7	0	III	T2N2M0	II	0
28	65	8	7	0	III	T4bN2M0	II	47
29	50	8	7	0	I	T1cN0Mx	III	45
30	62	7	6	0	III	T4bN2M0	II	54
31	52	8	7	0	III	T4bN2M0	III	50
32	62	4	6	0	III	T3N1M0	II	52
33	55	8	6	0	III	T3N1M0	II	52
34	68	3	7	0	II	T3N0M0	I	50
35	49	7	7	0	III	T3N1M0	I	0
36	43	7	8	0	III	T3N1M0	I	N/A
37	63	8	8	0	III	T4aN0Mx	II	40
38	62	7	7	0	N/A	N/A	II	54
39	52	8	7	0	II	T2N1M0	II	52
40	48	6	8	0	II	T2N0M0	II	0

Note: ^aPatients with bilateral breast cancer.

Abbreviations: ER, estrogen; PR, progesterone; rb, right breast tumor; lb, left breast tumor; N/A, not available; TNM, tumor, lymph nodes, metastasis.

exact test calculations ($P < 0.05$). Patients' Ct raw expression levels and blood count are available upon request.

Results

ER/PR expression and clinicopathological characteristics

All the patients included in this study were diagnosed with invasive ductal breast carcinomas. Twenty-three patients did not express ER or PR on the primary tumors, classifying the patients into the TNBC phenotype. The average age at the time

of diagnosis for each group was 54 years; 34% of the patients were under 50 years of age with a mean age of 45.7 years, while patients over 50 years of age had a mean age of 58.4 years. Twenty-five of the patients had reached menopause at the time of diagnosis. Approximately 46% of the patients already had grade III tumors, and almost all had positive lymph nodes, but with no detectable secondary distant tumors. The clinicopathological characteristics of the patients are presented in Table 1.

The correlations between the clinical data were done with respect to ER/PR expression in primary tumors (Table 2).

Table 2 Correlations between ER/PR status and patients' clinicopathological features

Patient characteristics	Number of patients	%	ER/PR+ Her2–	ER/PR– Her2–	P-value
All patients	40	100	17	23	
Age (years)					
≤50	13	34.15	6	7	1.000
>50	27	65.85	11	16	
Clinical stage					
I	2	4.87	1	1	0.731
II	14	34.15	5	9	
III	22	56.10	10	12	
Tumor size					
T1 and T2	19	43.35	7	12	0.747
T3 and T4	20	51.22	9	11	
Lymph nodes					
N0	6	14.64	4	2	0.450
N1	18	43.90	7	11	
N2	13	34.15	5	8	
N3	1	2.44	0	1	
Nottingham grading					
I	6	14.63	4	2	0.005**
II	15	39	10	5	
III	19	46.34	3	16	
Premenopause	5	12.20	2	3	1.000
Postmenopause	14	34.15	6	7	

Note: Percentage <100% is attributed to missing information. ** $P<0.01$.

Abbreviations: ER, estrogen; PR, progesterone.

No association was observed for age, clinical stage, tumor size, lymph nodes, or menopausal status. Statistical significance was observed between the tumor grading and the ER/PR status ($P<0.005$); more patients with ER/PR-negative tumors had grade III, while more patients with ER/PR-positive tumors had grade II.

ER/PR expression and blood gene profile

We profiled the expression of 84 key genes involved in the regulation of signal transduction in the inflammatory cascades as a response to immune reaction. We observed a change in expression for a panel of 14 genes between the ER/PR-positive/negative group (Table 3). All but three genes were downregulated in the blood of TNBC patients. We identified several interleukins as being of interest: *IL13*, *IL16*, *IL17C* and *F*, *IL1A*, *IL3*; interleukin receptors: *IL10RB*, *IL5RA*; chemokines: *CXCL13* and *CCL26*; and cytokines: *CSF2*, *IFNA2*, *OSM*, *TNFSF13*.

The data set was imported into IPA software to predict the chemical, molecular, and cellular interactions between these genes in the context of cellular phenotype and disease. Based on gene expression, the software predicted that these genes mediate the inflammatory response ($P=2.57\times10^{-12}$ – 1.8×10^{-3}) through cell-to-cell signaling and interaction ($P=1.4\times10^{-11}$ – 1.8×10^{-3}) in the hematological system development and function ($P=1.4\times10^{-11}$ – 1.8×10^{-4}). The main identified canonical pathway was, as expected, the cytokines' mediated communication between immune cells ($P=4.39\times10^{-12}$).

The software also generated two plausible regulatory networks, which we merged in order to get a more comprehensive view on how these genes are regulated and how they might interact with each other (Figure 1). Most of the identified molecules interact in the extracellular space and regulate each other's expression through direct (solid lines) or indirect (dashed lines) interactions. Furthermore, they seem to have the ability to self-regulate their expression (circular arrows that originate from one molecule and pointing back at that same molecule). To ascertain whether our findings are in accordance with the previous reports in the field, we ran our

Table 3 Gene differentially expressed in the blood of TNBC patients versus that of ER/PR+ patients

Gene	Name	Fold regulation	95% CI	Adj P-value
<i>IL10RB</i>	Interleukin 10 receptor, beta	1.83	(0.24, 3.42)	0.012
<i>IFNA2</i>	Interferon, alpha 2	1.58	(1.15, 2.01)	0.038
<i>CXCL13</i>	Chemokine (C-X-C motif) ligand 13	1.52	(1.24, 1.79)	0.002
<i>IL17C</i>	Interleukin 17C	–3.91	(–12.5, –2.32)	0.000
<i>IL17F</i>	Interleukin 17F	–3.38	(–12.5, –1.96)	0.004
<i>IL13</i>	Interleukin 13	–2.92	(–12.5, –1.64)	0.038
<i>CCL26</i>	Chemokine (C-C motif) ligand 26	–2.55	(–12.5, –1.4)	0.023
<i>CSF2</i>	Colony-stimulating factor 2 (granulocyte-macrophage)	–2.49	(0.21, 0.59)	0.008
<i>IL3</i>	Interleukin 3 (colony-stimulating factor, multiple)	–2.49	(–4.76, –1.7)	0.011
<i>OSM</i>	Oncostatin M	–2.42	(–7.14, –1.45)	0.021
<i>IL1A</i>	Interleukin 1, alpha	–1.96	(–3.57, –1.35)	0.036
<i>IL16</i>	Interleukin 16	–1.68	(–3.84, –1.07)	0.008
<i>IL5RA</i>	Interleukin 5 receptor, alpha	–1.62	(–2.85, –1.13)	0.041
<i>TNFSF13</i>	Tumor necrosis factor (ligand) superfamily, member 13	–1.54	(–2.32, –1.14)	0.025

Abbreviations: TNBC, triple-negative breast cancer; ER, estrogen; PR, progesterone; CI, confidence interval; Adj, adjusted.

© 2000–2015 QIAGEN. All rights reserved.

Figure 1 IPA prediction of the interactive network between the differentially expressed genes in the blood of triple negative compared to ER/PR+ breast cancer patients. **Notes:** Red – genes overexpressed; Green – genes underexpressed. Data were analyzed through the use of QIAGEN's Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity).

Abbreviations: IPA, Ingenuity Pathway Analysis; ER, estrogen; PR, progesterone.

gene expression results through a Molecule Activity Predictor (MAP) algorithm. We observed that most of the identified gene expression levels corresponded to predicted inhibition (blue arrows) or activation (pink arrows) by the upstream/downstream molecules. However, there were exceptions with the literature findings of OSM regulation of CXCL13 expression and IL3 regulation of IL5RA expression, which in our study seem to be the opposite of what was predicted. *CSF2* seems to be a nodal molecule in our network, its expression being regulated by OSM, IL3, TNFSF13, IL1A, IL17, and IFN- α , and in turn regulates the expression of other molecules through positive feedback loops as in the case of IFN- α , OSM, and IL1A.

According to our results, upregulation of IFNA2 and IFN- α suggests an activation of downstream signaling cascade through IL10RB receptors, while downregulation of *CSF2* expression suggests signaling repression through IL5RA receptors.

ER/PR expression and white cells count

On the basis of gene expression results, we retrospectively examined each patient's chart for the white blood cells count at the time of blood collection. Most of the patients had cell counts within the normal limits; however, we did observe differences in the individual cell population distribution (Table 4). The TNBC group had almost two times less

Table 4 Patients' differential blood count according to ER/PR expression on the primary tumors

Cell type	Reference values	ER/PR–	ER/PR+	P-value
White blood cells	4,000–10,000/ μ L	7,340 $\pm$ 321	7,780 $\pm$ 555	0.72
Neutrophils	2,000–8,000/ μ L	4,864 $\pm$ 273	4,689 $\pm$ 345	0.51
	45%–80%	65.6 $\pm$ 1.2	60.6 $\pm$ 1.8	0.05*
Eosinophils	50–700/ μ L	101 $\pm$ 19	195 $\pm$ 60	0.06
	$\leq$ 1.5%	1.4 $\pm$ 0.2	22 $\pm$ 0.4	0.11
Basophils	$\leq$ 200/ μ L	21 $\pm$ 3	27 $\pm$ 4	0.21
	$\leq$ 0.2%	0.3 $\pm$ 0	0.3 $\pm$ 0	0.33
Lymphocytes	1,000–4,000/ μ L	1,805 $\pm$ 71	2,304 $\pm$ 230	0.03*
	20%–55%	25.2 $\pm$ 1.1	29.5 $\pm$ 1.9	0.05*
Monocytes	300–1,000/ μ L	545 $\pm$ 33	565 $\pm$ 48	0.83
	$\leq$ 15%	7.5 $\pm$ 0.3	7.4 $\pm$ 0.5	0.78
Thrombocytes	150,000–450,000/ μ L	268,000 $\pm$ 19,696	264,765 $\pm$ 18,055	0.93

Notes: Data presented as mean $\pm$ standard error. * $P < 0.05$.

Abbreviations: ER, estrogen; PR, progesterone.

eosinophils than the ER/PR+ group, but the difference was not significant, although the trend is clearly evident ($P=0.06$). Significant differences ($P < 0.03$) were observed for the lymphocyte counts, which were approximately 30% lower in the TNBC group compared with ER/PR+. The differences between the other cell types were negligible.

Discussion

Increasing evidence suggests that the immune system can influence breast tumors' initiation, progression, and response to therapy; furthermore, the chemotherapeutic effect of some conventional drugs such as doxorubicin seems to be mediated through immunological signaling pathways.⁹ In a previous study,¹⁰ we observed that primary tumor molecular features induce distinct gene expression levels in the peripheral blood of breast cancer patients, genes that are known to be involved in immune signaling. Therefore, in this study, we wanted to gain a more comprehensive view of the baseline immunological status of our patients by investigating the expression profile of several cytokines, chemokines, interleukins and their receptors, as these are the direct mediators of the immune response. Expression of ER, PR, and Her2 has been previously associated with distinct patterns of cytokines stimuli;^{11,12} however, these studies evaluated a variable series of breast cancer cases and a limited panel of cytokines. Our study does not suffer from these limitations; we evaluated a broad panel of molecules, and our analysis was restricted to a homogeneous group of Her2– patients (ER+, PR+ vs ER, PR–).

TNBC patients have the worst outcome of all breast cancer patients, regardless of the stage at diagnosis.¹³ Specific clinical features include early age at onset, premenopausal status, and prevalence among racial/ethnicity population.

Although no relation was observed with tumor size and node positivity,¹⁴ these patients are more likely to develop visceral metastases,^{15,16} suggesting that the metastatic spread occurs predominantly through hematogenous mechanisms (reviewed in Rastelli et al¹⁷). The analysis of the clinicopathological data of our patients showed that the TNBC patients enrolled in this study present clinical factors associated with poor prognosis, such as advanced tumor grade at time of diagnosis¹⁸ and a reduced number of eosinophils¹⁹ and lymphocytes.^{19–21} Although we did not reach statistical significance in blood eosinophils count, the difference between the two cohorts of patients is clear ($P < 0.06$). Eosinophils can have both pro- and anti-inflammatory and immunoregulatory activities, and therefore, the role of these cells in cancer is still unclear; however, lower counts of eosinophils in breast patients have been associated with worse prognosis.¹⁹ Eosinophils production and activation requires IL-5, IL-3, and CSF2, and they also display high-affinity receptors of IL-5.²² We did find significant lower levels for *IL-3*, *CSF2*, and *IL5RA* gene expressions in the peripheral blood of TNBC patients, which could be responsible for the lower count of eosinophils.

Pretreatment lymphopenia has been associated not only with poor cancer survival, but also with poor response to chemotherapy and radiotherapy, thereby also suggesting predictive potential value.^{20,23} Lymphocytopenia was previously reported as an important predictive, prognostic, and survival parameter in metastatic breast cancer;²⁴ however, this is the first report that specifically associates lower counts of lymphocytes with TNBC phenotype. We hypothesize that this could be one of the factors that influence the disease-free and overall survival of these patients. The lymphocyte levels indicate the cell-mediated immunity status, which is important in the host's defense against tumors. Low counts

of lymphocytes could reveal a previous immunosuppressed state, and therefore an inappropriate host response.²¹ Suppressions of lymphocyte levels might be a tumor progression mechanism,²⁵ therefore indicating a therapeutic potential for lymphocytopenia correctors such as anti-CTLA4 antibody, IL-7 LGF, etc.²⁴

The most downregulated cytokines in the TNBC group were *IL-17C* and *IL-17F*, which belong to the IL-17 family of cytokines and cooperate to induce tissue inflammation through T helper 17 cells (Th17). IL-17C, better known as IL-21, is produced by the lymphoid population and shows pleiotropic actions on both lymphoid and nonlymphoid cells, indicating broad functions with implications in innate and adaptive immune response, inflammation, allergies, and cancer (reviewed in Spolski and Leonard²⁶). C > T polymorphism in the promoter region of *IL-21* has been shown to control the transcriptional levels, the CT/TT genotypes having a higher transcriptional activity²⁷ with better prognosis and higher survival probability than the CC genotype.²⁷ Whether the incidence of CT/TT genotypes is lower in TNBC compared to ER/PR+ patients remains to be investigated, but could explain the reduced levels of *IL-21* in TNBC patients. Recent reports have indicated that *IL-21* is a negative regulator of Treg development,²⁸ prevailing the Treg-mediated immunosuppression.^{29,30} Downregulation of IL-21 in TNBC patients' blood might lead to increased Tregs, which have been associated with a poor prognosis in patients with early breast cancer.³¹ Also, IL-21 has been reported to have strong antitumor effects by increasing cytotoxicity toward cancer cells,³² including breast cancer cells,³³ by directing CD8⁺ T-cells to infiltrate tumors.³⁴ Reduced blood IL-21 levels in TNBC patients might be an indicator of the tumor-infiltrating lymphocytes (TILs) status (especially of those of the CD8⁺), which has been shown to be predictive of therapy outcome.³⁵

Triple-negative breast tumors present high vascular endothelial growth factor (VEGF) concentrations³⁶ and increased micrometastases that seem to be angiogenesis dependent,³⁷ and IL-21 has been shown to inhibit tumor angiogenesis.³⁸ Breast cancer angiogenesis has also been shown to be regulated by *CSF2*, which stimulates monocytes³⁹ and macrophages⁴⁰ to produce VEGFR1 that binds and inactivates VEGF. Reduced IL-21 and CSF2 levels could suggest increased angiogenesis in these patients. CSF2 also enhances macrophage antigen presentation and immune response.⁴¹ Breast cancer patients who received CSF2 showed substantial activity in controlling the disease,⁴² and patients treated after transplant lived longer and had fewer relapses.⁴³

OSM is secreted in low amounts by resting circulating cells such as macrophages, neutrophils, and T lymphocytes;^{44,45} however, when these cells get activated, they quickly express OSM. This molecule has been shown to have pleiotropic effects: whereas it can inhibit breast cancer cells proliferation in vitro, recent studies have also shown that they effectively mediate macrophage-assisted⁴⁵ cancer progression.⁴⁴ OSM secretion is conditioned by cell priming with tumor cells;^{44,45} furthermore, in neutrophils, OSM release seems to be CSF2 dependent.⁴⁴ Both cohorts of our patients have shown similar neutrophil counts concomitantly with reduced blood expression of CSF2 and OSM, suggesting that neutrophils in TNBC patients are rather in a “resting” state.

We identified several other molecules to be differentially expressed between the two groups of patients; however, the available literature regarding their role in breast cancer immune status is limited, warranting further investigations into their association with treatment response. IL-1A⁴⁶ is secreted by macrophages and monocytes and has been shown to stimulate breast cancer proliferation. TNFSF13 is important for B-cell development, and IL-16 has been identified as a critical chemotactic factor that contributes to monocytes' and macrophages' migration toward tumor cells.⁴⁷

Conclusion

Overall, our findings suggest that the evaluation of the immunologic blood profile in TNBC patients may yield important clinical information to guide breast cancer prognosis and therapy. We showed a distinct systemic cytokine profile associated with the ER/PR expression on breast tumors, results that could also explain the singular behavior of each of the tumor subtypes, allowing future immunotherapeutic interventions. Furthermore, these results could contribute to a better understanding of the possible role of antitumor immune responses in mediating the clinical outcome. The recent initiation of the first clinical trials regarding targeted T-cells immunotherapy of TNBC patients ([ClinicalTrials.gov](https://clinicaltrials.gov/Identifier/NCT01147016) Identifier: NCT01147016, NCT02316457) attests to the relevance of the results presented.

Acknowledgments

This work was financed by the POSCCE 709/2010 grant with the title: “Clinical and economical impact of proteome and transcriptome molecular profiling in neoadjuvant therapy of triple negative breast cancer (BREASTIMPACT)”, and published under the aegis of the European Social Fund, Human Resources Development Operational Programme 2007–2013, project number: POSDRU/159/1.5/S/138776.

Disclosure

The authors report no conflicts of interest in this work.

References

- American Cancer Society. *Global Cancer Facts & Figures 2nd Edition*. Atlanta, GA: American Cancer Society; 2011.
- Guiu S, Michiels S, Andre F, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. *Ann Oncol*. 2012;23(12):2997–3006.
- Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. *Clin Med Res*. 2009;7(1–2):4–13.
- Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet*. 2001;357(9255):539–545.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–674.
- Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. *Semin Cancer Biol*. 2002;12(2):113–120.
- Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. *J Clin Invest*. 2011;121(10):3804–3809.
- Levano KS, Jung EH, Kenny PA. Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines. *Biochem Biophys Res Commun*. 2011;411(1):107–110.
- Andre F, Dieci MV, Dubsky P, et al. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. *Clin Cancer Res*. 2013;19(1):28–33.
- Tudoran O, Virtic O, Balacescu L, et al. Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients. *PLoS One*. 2014;9(7):e102764.
- Herrera AC, Panis C, Victorino VJ, et al. Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients. *Cancer Immunol Immunother*. 2012;61(11):2193–2201.
- Muraro E, Martorelli D, Turchet E, et al. A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. *Breast Cancer Res*. 2011;13(6):R117.
- Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res*. 2007;13(15 Pt 1):4429–4434.
- Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. *Breast J*. 2009;15(5):454–460.
- Ihemelandu CU, Naab TJ, Mezgebe HM, et al. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women. *Am J Surg*. 2008;195(2):153–158.
- Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. *J Clin Oncol*. 2006;24(36):5652–5657.
- Rastelli F, Biancanelli S, Falzetta A, et al. Triple-negative breast cancer: current state of the art. *Tumori*. 2010;96(6):875–888.
- Howlader N, Noone AM, Krapcho M, Garshell J, et al (editors). *SEER Cancer Statistics Review, 1975–2010*. Bethesda, MD: National Cancer Institute; 2013.
- Owby HE, Roi LD, Isenberg RR, Brennan MJ. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. *Cancer*. 1983;52(1):126–130.
- Vicente Conesa MA, Garcia-Martinez E, Gonzalez Billalabeitia E, et al. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. *Breast*. 2012;21(4):468–474.
- Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. *Cancer Res*. 2009;69(13):5383–5391.
- Rothenberg ME, Hogan SP. The eosinophil. *Annu Rev Immunol*. 2006;24:147–174.
- Huang JJ, Jiang WQ, Lin TY, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. *Ann Oncol*. 2011;22(1):149–155.
- De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. *Clin Breast Cancer*. 2012;12(4):264–269.
- Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. *Pancreas*. 2006;32(1):22–28.
- Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. *Curr Opin Immunol*. 2008;20(3):295–301.
- You Y, Deng J, Zheng J, et al. IL-21 gene polymorphism is associated with the prognosis of breast cancer in Chinese populations. *Breast Cancer Res Treat*. 2013;137(3):893–901.
- Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. *Nature*. 2007;448(7152):484–487.
- Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. *J Immunol*. 2007;178(2):732–739.
- Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. *Blood*. 2008;111(1):229–235.
- Menetrier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. *Cancer Res*. 2009;69(20):7895–7898.
- Tian Y, Yuan C, Ma D, et al. IL-21 and IL-12 inhibit differentiation of Treg and TH17 cells and enhance cytotoxicity of peripheral blood mononuclear cells in patients with cervical cancer. *Int J Gynecol Cancer*. 2011;21(9):1672–1678.
- Park YK, Shin DJ, Cho D, et al. Interleukin-21 increases direct cytotoxicity and IFN-gamma production of ex vivo expanded NK cells towards breast cancer cells. *Anticancer Res*. 2012;32(3):839–846.
- Sondergaard H, Frederiksen KS, Thygesen P, et al. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. *Cancer Immunol Immunother*. 2007;56(9):1417–1428.
- West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. *Breast Cancer Res*. 2011;13(6):R126.
- Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. *Cancer Res*. 2001;61(14):5407–5414.
- Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. *Nat Med*. 1995;1(2):149–153.
- Castermans K, Tabruyn SP, Zeng R, et al. Angiostatic activity of the antitumor cytokine interleukin-21. *Blood*. 2008;112(13):4940–4947.
- Eubank TD, Roberts R, Galloway M, Wang Y, Cohn DE, Marsh CB. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. *Immunity*. 2004;21(6):831–842.
- Eubank TD, Roberts RD, Khan M, et al. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. *Cancer Res*. 2009;69(5):2133–2140.
- Armstrong CA, Botella R, Galloway TH, et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. *Cancer Res*. 1996;56(9):2191–2198.
- Kurbacher CM, Kurbacher JA, Cramer EM, et al. Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma. *Oncology (Williston Park)*. 2005;19(4 Suppl 2):23–26.

43. Kuzhan O, Ozet A, Ulutin C, et al. Survival benefit with GM-CSF use after high-dose chemotherapy in high-risk breast cancer. *Tumori*. 2007;93(6):550–556.
44. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. *Cancer Res*. 2005;65(19):8896–8904.
45. Vlaicu P, Mertins P, Mayr T, et al. Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. *BMC Cancer*. 2013;13:197.
46. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. *Cytokine Growth Factor Rev*. 2006;17(5):325–337.
47. Milke L, Schulz K, Weigert A, Sha W, Schmid T, Brune B. Depletion of tristetraprolin in breast cancer cells increases interleukin-16 expression and promotes tumor infiltration with monocytes/macrophages. *Carcinogenesis*. 2013;34(4):850–857.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress